Monday, August 07, 2023
Ginkgo Bioworks (NYSE: DNA) has declared a novel collaboration with Merck, also known as MSD internationally, to concentrate on enhancing biologic manufacturing. This move underscores Ginkgo's role in advancing cell programming and biosecurity as a frontrunner in the field.
Ginkgo Bioworks, a pioneer in cell programming and biosecurity, is set to leverage its expertise in cell engineering, ultra high-throughput multiplexed screening, protein characterization, and process optimization to enhance the efficiency and yield of biologic manufacturing. The collaboration agreement opens the door for Ginkgo to potentially receive up to $490 million, encompassing upfront research fees, research milestone fees, option license payments, and commercial milestone payments.
Jason Kelly, the CEO and co-founder of Ginkgo Bioworks, expressed his excitement about the partnership: "We're enthusiastic about teaming up with Merck to revolutionize biologics production. By utilizing our distinctive capabilities in predictive ultra high-throughput multiplexed screening, product characterization, and process optimization, we look forward to making a substantial impact alongside our counterparts at Merck."
Dr. Michael Kress, the senior vice president of development sciences and clinical supply at Merck Research Laboratories, emphasized the shared commitment to innovation: At Merck, we're constantly exploring innovative approaches to enhance efficiency while upholding product quality. Our ongoing collaboration with Ginkgo Bioworks is a testament to this commitment.
